Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 multi-part study of MTX325 in healthy volunteers and patients with Parkinson's disease
NL-OMON61165Phase 1Not yet recruiting
- Sponsor
- Mission Therapeutics
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of MTX325 in Parkinson's disease (PD) (2 cohorts), sponsored by Mission Therapeutics. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
MTX325
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON61165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61165.